Mild cognitive impairment clinical trials

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Most investigators believe that by the time the clinical diagnosis of Alzheimer's disease has been made, sufficient neuronal damage has taken place in the brain to make reversal of the condition unlikely. Prevention would be a more appealing strategy, but the challenges of conducting true primary prevention trials in asymptomatic persons are formidable. The duration and expense of these types of trial make them unappealing. Large numbers of subjects would need to be followed for many years, and without a promising therapeutic agent, this approach would be risky. Hence, the concept of secondary prevention treatment trials involving minimally symptomatic individuals, such as persons with mild cognitive impairment (MCI) - a transitional stage between normal ageing and very early Alzheimer's disease - has evolved and seems more promising. This concept has led to the emergence of a number of clinical trials for MCI, which are discussed here.

Original languageEnglish (US)
Pages (from-to)646-653
Number of pages8
JournalNature Reviews Drug Discovery
Volume2
Issue number8
StatePublished - Aug 2003

Fingerprint

Alzheimer Disease
Clinical Trials
Primary Prevention
Secondary Prevention
Research Personnel
Brain
Therapeutics
Cognitive Dysfunction

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Mild cognitive impairment clinical trials. / Petersen, Ronald Carl.

In: Nature Reviews Drug Discovery, Vol. 2, No. 8, 08.2003, p. 646-653.

Research output: Contribution to journalArticle

@article{8f807dab1c8b4565b5fcbafe3628586f,
title = "Mild cognitive impairment clinical trials",
abstract = "Most investigators believe that by the time the clinical diagnosis of Alzheimer's disease has been made, sufficient neuronal damage has taken place in the brain to make reversal of the condition unlikely. Prevention would be a more appealing strategy, but the challenges of conducting true primary prevention trials in asymptomatic persons are formidable. The duration and expense of these types of trial make them unappealing. Large numbers of subjects would need to be followed for many years, and without a promising therapeutic agent, this approach would be risky. Hence, the concept of secondary prevention treatment trials involving minimally symptomatic individuals, such as persons with mild cognitive impairment (MCI) - a transitional stage between normal ageing and very early Alzheimer's disease - has evolved and seems more promising. This concept has led to the emergence of a number of clinical trials for MCI, which are discussed here.",
author = "Petersen, {Ronald Carl}",
year = "2003",
month = "8",
language = "English (US)",
volume = "2",
pages = "646--653",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Mild cognitive impairment clinical trials

AU - Petersen, Ronald Carl

PY - 2003/8

Y1 - 2003/8

N2 - Most investigators believe that by the time the clinical diagnosis of Alzheimer's disease has been made, sufficient neuronal damage has taken place in the brain to make reversal of the condition unlikely. Prevention would be a more appealing strategy, but the challenges of conducting true primary prevention trials in asymptomatic persons are formidable. The duration and expense of these types of trial make them unappealing. Large numbers of subjects would need to be followed for many years, and without a promising therapeutic agent, this approach would be risky. Hence, the concept of secondary prevention treatment trials involving minimally symptomatic individuals, such as persons with mild cognitive impairment (MCI) - a transitional stage between normal ageing and very early Alzheimer's disease - has evolved and seems more promising. This concept has led to the emergence of a number of clinical trials for MCI, which are discussed here.

AB - Most investigators believe that by the time the clinical diagnosis of Alzheimer's disease has been made, sufficient neuronal damage has taken place in the brain to make reversal of the condition unlikely. Prevention would be a more appealing strategy, but the challenges of conducting true primary prevention trials in asymptomatic persons are formidable. The duration and expense of these types of trial make them unappealing. Large numbers of subjects would need to be followed for many years, and without a promising therapeutic agent, this approach would be risky. Hence, the concept of secondary prevention treatment trials involving minimally symptomatic individuals, such as persons with mild cognitive impairment (MCI) - a transitional stage between normal ageing and very early Alzheimer's disease - has evolved and seems more promising. This concept has led to the emergence of a number of clinical trials for MCI, which are discussed here.

UR - http://www.scopus.com/inward/record.url?scp=0042067944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042067944&partnerID=8YFLogxK

M3 - Article

C2 - 12904814

AN - SCOPUS:0042067944

VL - 2

SP - 646

EP - 653

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 8

ER -